Celgene-backed antibody therapy developer Northern Biologics has extended its series A round and merged with oncology treatment developer Mosaic Biomedicals.

Bio-Techne has made a strategic investment in Astute Medical, which already counts corporates Fosun, Johnson & Johnson and Kaiser Permanente as shareholders.

Private equity partnership Boston Millennia Partners has joined a round that already includes corporates Celgene, Novartis, Foundation Medicine and HealthScape Advisors.

A $4m investment by pharmaceutical company Astellas's corporate venturing unit has been added to the $57m Oncorus raised from backers including Celgene in July.

In April 2014, Transcend completed a $22m series C round from existing investors and an undisclosed global pharmaceutical and medical device company.

The healthcare provider has launched a venture fund, Inova Strategic Investments, as well as an accelerator that will invest up to $325,000 in startups.